Savara Inc. (SVRA) – What Are Investment Firms Saying About This Stock?

Posted by Brenda Bartman on Oct 18th, 2026

Shares of Savara Inc. (NASDAQ:SVRA – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $10.25.

A number of research firms have weighed in on SVRA. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a research note on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday. JPMorgan Chase & Co. assumed coverage on Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Finally, Citigroup reiterated a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th.

Check Out Our Latest Report on Savara

Institutional Trading of Savara

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its stake in shares of Savara by 96.5% in the 1st quarter. Renaissance Technologies LLC now owns 652,672 shares of the company’s stock valued at $3,564,000 after buying an additional 320,572 shares during the period. Walleye Capital LLC acquired a new stake in shares of Savara during the 2nd quarter worth approximately $1,532,000. BlackRock Inc. acquired a new stake in shares of Savara during the 2nd quarter worth approximately $76,966,000. Deutsche Bank AG purchased a new stake in shares of Savara during the 2nd quarter valued at approximately $5,328,000. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Savara during the 2nd quarter valued at approximately $42,977,150. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Price Performance

Shares of NASDAQ SVRA opened at $4.45 on Tuesday. The firm has a 50-day simple moving average of $5.23 and a 200-day simple moving average of $5.40. The stock has a market capitalization of $914.30 million, a price-to-earnings ratio of -7.67 and a beta of 0.20. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. Savara has a 52 week low of $3.49 and a 52 week high of $7.01.

Savara (NASDAQ:SVRA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, equities analysts predict that Savara will post -0.66 earnings per share for the current fiscal year.

About Savara

(Get Free Report)

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.